Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.72 USD
Change Today +0.04 / 1.49%
Volume 93.0K
OREX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 9:51 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Open
$2.73
Previous Close
$2.68
Day High
$2.74
Day Low
$2.67
52 Week High
03/3/15 - $9.37
52 Week Low
09/1/15 - $2.60
Market Cap
341.1M
Average Volume 10 Days
2.7M
EPS TTM
$-0.23
Shares Outstanding
125.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (OREX)

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

47 Employees
Last Reported Date: 02/27/15
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $640.6K
Chief Business & Financial Officer and Treasu...
Total Annual Compensation: $379.3K
Head of Global Development and Executive Vice...
Total Annual Compensation: $379.3K
Compensation as of Fiscal Year 2014.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Orexigen Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $5,194,000 compared to $857,000 a year ago. Loss from operations was $20,728,000 compared to $22,802,000 a year ago. Net loss was $22,504,000 or $0.18 per basic and diluted share compared to $24,507,000 or $0.21 per basic and diluted share a year ago. For the six months period, the company reported total revenues of $9,553,000 compared to $1,714,000 a year ago. Loss from operations was $36,195,000 compared to $45,956,000 a year ago. Net loss was $39,737,000 or $0.32 per basic and diluted share compared to $49,405,000 or $0.43 per basic and diluted share a year ago.

Orexigen Therapeutics, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Orexigen Therapeutics, Inc. announced that they will report Q2, 2015 results at 8:00 AM, US Eastern Standard Time on Aug 06, 2015

Orexigen Therapeutics, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Orexigen Therapeutics, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $2.72 USD +0.04

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $2.60 USD +0.04
GlaxoSmithKline PLC 1,326 GBp +30.50
Novo Nordisk A/S kr364.50 DKK +5.90
VIVUS Inc $1.14 USD -0.03
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.